Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05667948

Molecular Analysis and Treatment Options of Thymic Malignancies

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.

In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Xiaomin Niu

Shanghai, Shanghai Municipality, 200030, China

Location status: Recruiting

Location contact

Xiaomin Niu

CONTACT

[email protected]

021-22200000

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically proven diagnosis of thymic malignancies
  • 18 years of age or older
  • Ability to understand and the willingness to sign a written informed consent document

Treatment and study plan

Chemotherapy

Drug

different treatments based on the molecular analysis

Other names: targeted therapy, immunotherapy

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: 20 years

    Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

  2. Disease control rate (DCR)

    Time frame: 20 years

    Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

  3. Progression-free survival (PFS)

    Time frame: 20 years

    Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Secondary outcomes

  1. Overall survival (OS)

    Time frame: 20 years

    Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Sponsors and collaborators

Lead sponsor

Shanghai Chest Hospital

Other

Registry information

Official study title

Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors

Important dates

Study start
2016
Primary completion
2025
Study completion
2026
First posted
Dec 29, 2022
Registry last updated
May 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.